Neuren Media and Analyst Coverage, page-1151

Hi Trademil,

I didn’t put the valuation in that post I referenced Hassan he is fairly respected credentials in the industry.

i have said this before it the most accurate valuation of Neus pipeline to date.

Whilst there are the differences you note there a lot of potential postives with 2591 that a suitor potentially picks up that you are failing to consider when comparing 2591 to skyclavs deal…. That’s is the potential additional single figure indications that 2591 may offer as a platform drug….. and not to mention the out standing results to date to warrant perhaps a platform drug…..so some differences ….. hypothetically peaks sales could be conservatively US$50-70bn, maybe $100bn… thats what an Aquire could be buying here potentially